Drugs / ALXN2350
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07218887 | Oct 2025 → Jan 2032 expected | dilated cardiomyopathy 1HH | Alexion Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALXN2350 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07218887 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “ALXN2350 is a gene therapy product consisting of an AAV9 capsid containing BAG3 transgene.” NCT07218887 ↗ |
| Route | Intravenous | “It is administered as a single intravenous (IV) infusion.” NCT07218887 ↗ |